Wednesday, May 28, 2025 9:06:13 PM
Christopher Missling, PhDChristopher Missling, PhD
• FollowingFollowing
CEO | Biotech Leader | Driving Breakthroughs in Precision Medicine for CNS Disorders | Innovating with Blarcamesine (ANAVEX®2-73)CEO | Biotech Leader | Driving Breakthroughs in Precision Medicine for CNS Disorders | Innovating with Blarcamesine (ANAVEX®2-73)
3w • 3 weeks ago • Visible to anyone on or off LinkedIn
How does the human brain changes across a lifespan …?
🚀 Researchers recently published in Nature Neuroscience findings that the strength and diversity of connections between different parts of the brain peak in early and mid-adulthood. Source: https://lnkd.in/eNNSc2Ez
🤝 From birth to the last moments of life, the human brain is known to change and evolve significantly, both in terms of its physical organization (i.e., structural connectivity) and the coordination between different brain regions (i.e., functional connectivity).
💡 Mapping and understanding the brain's evolution over time is of crucial importance, as it could also shed light on differences in the brains of individuals who develop various mental health disorders or experience an aging-related cognitive decline.
🧬 Moreover, the team's comprehensive analyses could help uncover new deviations in the brain's functional connectivity linked to specific neuropsychiatric or neurodegenerative disorders.
🏆 Recent results in this area:
Blarcamesine, an oral treatment, may slow brain volume loss in Alzheimer's. Safe over four years, blarcamesine slowed decline by up to 50% on a key cognitive test. Source: https://lnkd.in/eZMgFw78
These results may offer hope for patients and families
• FollowingFollowing
CEO | Biotech Leader | Driving Breakthroughs in Precision Medicine for CNS Disorders | Innovating with Blarcamesine (ANAVEX®2-73)CEO | Biotech Leader | Driving Breakthroughs in Precision Medicine for CNS Disorders | Innovating with Blarcamesine (ANAVEX®2-73)
3w • 3 weeks ago • Visible to anyone on or off LinkedIn
How does the human brain changes across a lifespan …?
🚀 Researchers recently published in Nature Neuroscience findings that the strength and diversity of connections between different parts of the brain peak in early and mid-adulthood. Source: https://lnkd.in/eNNSc2Ez
🤝 From birth to the last moments of life, the human brain is known to change and evolve significantly, both in terms of its physical organization (i.e., structural connectivity) and the coordination between different brain regions (i.e., functional connectivity).
💡 Mapping and understanding the brain's evolution over time is of crucial importance, as it could also shed light on differences in the brains of individuals who develop various mental health disorders or experience an aging-related cognitive decline.
🧬 Moreover, the team's comprehensive analyses could help uncover new deviations in the brain's functional connectivity linked to specific neuropsychiatric or neurodegenerative disorders.
🏆 Recent results in this area:
Blarcamesine, an oral treatment, may slow brain volume loss in Alzheimer's. Safe over four years, blarcamesine slowed decline by up to 50% on a key cognitive test. Source: https://lnkd.in/eZMgFw78
These results may offer hope for patients and families
Recent AVXL News
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
- Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference • GlobeNewswire Inc. • 11/26/2025 12:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 11/25/2025 09:31:44 PM
